Abstract: The present invention provides a seminal plasma complex quality control serum, which is freeze-dried powders prepared by mixing a quality control serum preservation solution and a seminal plasma stock solution; wherein the quality control serum preservation solution is an aqueous solution containing 0.47% to 0.67% saccharides, 0.07% to 0.17% salts and 0.63% to 0.83% enzyme stabilizers; the seminal plasma stock solution is the seminal plasma obtained after the direct centrifugation of completely liquefied fresh human semen; and a mixing ratio by volume of the quality control serum preservation solution to the seminal plasma stock solution is 1:100 to 100:1. According to the present invention, a specific quality control serum preservation solution is used, then mixed with the seminal plasma at a suitable ratio by volume and finally subjected to freeze-drying treatment.

Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

Abstract: The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.

Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.

Abstract: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.

Abstract: The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.